Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > Articles online first > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2021 Jan 26

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

 

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2021 Jan 26

DOI: 10.23736/S1824-4785.21.03334-3

Copyright © 2021 EDIZIONI MINERVA MEDICA

language: English

Medical treatment of thyrotoxicosis

Lorenzo SCAPPATICCIO 1 , Giuseppe BELLASTELLA 1, 2, Maria Ida MAIORINO 1, 2, Luca GIOVANELLA 3, 4, Katherine ESPOSITO 2, 5

1 Unit of Endocrinology and Metabolic Diseases, University of Campania L. Vanvitelli, Naples, Italy; 2 Department of Advanced Medical and Surgical Sciences, University of Campania L. Vanvitelli, Naples, Italy; 3 Clinic for Nuclear Medicine and Competence Center for Thyroid Diseases, Imaging Institute of Southern Switzerland, Bellinzona, Switzerland; 4 Clinic for Nuclear Medicine, University Hospital and University of Zurich, Zurich, Switzerland; 5 Diabetes Unit, University of Campania L. Vanvitelli, Naples, Italy


PDF


Medical treatment is the primary therapeutic option for thyrotoxicosis/hyperthyroidism. Two groups of causes of thyrotoxicosis (i.e. thyrotoxicosis with hyperthyroidism and thyrotoxicosis without hyperthyroidism) need to be considered for therapeutic reasons. Herein we provide an updated review on the role of conventional medical therapies [i.e. β-blockers, anti-thyroid drugs (ATDs), corticosteroids, inorganic iodide, perchlorate, cholecystographic agents, lithium, cholestyramine] in the main causes of thyrotoxicosis, starting from the rationale subtending their clinical application.


KEY WORDS: Thyrotoxicosis; Hyperthyroidism; Therapy; Drugs

top of page